Literature DB >> 26497481

Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.

Keith S Kaye1, Jason M Pogue2.   

Abstract

Infections caused by resistant gram-negative bacteria are becoming increasingly prevalent and now constitute a serious threat to public health worldwide because they are difficult to treat and are associated with high morbidity and mortality rates. In the United States, there has been a steady increase since 2000 in rates of extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii, particularly among hospitalized patients with intraabdominal infections, urinary tract infections, ventilator-associated pneumonia, and bacteremia. Colonization with resistant gram-negative bacteria is common among residents in long-term care facilities (particularly those residents with an indwelling device), and these facilities are considered important originating sources of such strains for hospitals. Antibiotic resistance is associated with a substantial clinical and economic burden, including increased mortality, greater hospital and antibiotic costs, and longer stays in hospitals and intensive care units. Control of resistant gram-negative infections requires a comprehensive approach, including strategies for risk factor identification, detection and identification of resistant organisms, and implementation of infection-control and prevention strategies. In treating resistant gram-negative infections, a review of surveillance data and hospital-specific antibiograms, including resistance patterns within local institutions, and consideration of patient characteristics are helpful in guiding the choice of empiric therapy. Although only a few agents are available with activity against resistant gram-negative organisms, two recently released β-lactam/β-lactamase inhibitor combinations - ceftolozane/tazobactam and ceftazidime/avibactam - have promising activity against these organisms. In this article, we review the epidemiology, risk factors, and antibiotic resistance mechanisms of gram-negative organisms. In addition, an overview of treatment options for patients with these infections is provided.
© 2015 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  avibactam; carbapenemase; ceftolozane; extended-spectrum β-lactamase; gram-negative bacteria; multidrug resistance

Mesh:

Substances:

Year:  2015        PMID: 26497481     DOI: 10.1002/phar.1636

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  98 in total

Review 1.  Carbapenem-Resistant Non-Glucose-Fermenting Gram-Negative Bacilli: the Missing Piece to the Puzzle.

Authors:  Thomas J Gniadek; Karen C Carroll; Patricia J Simner
Journal:  J Clin Microbiol       Date:  2016-02-24       Impact factor: 5.948

2.  Global Characterization of Protein Secretion from Human Macrophages Following Non-canonical Caspase-4/5 Inflammasome Activation.

Authors:  Martina B Lorey; Katriina Rossi; Kari K Eklund; Tuula A Nyman; Sampsa Matikainen
Journal:  Mol Cell Proteomics       Date:  2017-02-14       Impact factor: 5.911

3.  Risk factors for sepsis in patients with struvite stones following percutaneous nephrolithotomy.

Authors:  Xiaomin Gao; Chaoyue Lu; Fei Xie; Ling Li; Min Liu; Ziyu Fang; Zeyu Wang; Shaoxiong Ming; Hao Dong; Rong Shen; Yinghao Sun; Yonghan Peng; Xiaofeng Gao
Journal:  World J Urol       Date:  2019-04-09       Impact factor: 4.226

Review 4.  The Current State of Antimicrobial Stewardship: Challenges, Successes, and Future Directions.

Authors:  Jennifer Emberger; Dan Tassone; Michael P Stevens; J Daniel Markley
Journal:  Curr Infect Dis Rep       Date:  2018-06-29       Impact factor: 3.725

5.  Substrate Trapping in the Siderophore Tailoring Enzyme PvdQ.

Authors:  Kenneth D Clevenger; Romila Mascarenhas; Daniel Catlin; Rui Wu; Neil L Kelleher; Eric J Drake; Andrew M Gulick; Dali Liu; Walter Fast
Journal:  ACS Chem Biol       Date:  2017-02-15       Impact factor: 5.100

6.  Multi-Drug-Resistant Gram-Negative Infections in Deployment-Related Trauma Patients.

Authors:  Wesley R Campbell; Ping Li; Timothy J Whitman; Dana M Blyth; Elizabeth R Schnaubelt; Katrin Mende; David R Tribble
Journal:  Surg Infect (Larchmt)       Date:  2017-02-24       Impact factor: 2.150

Review 7.  Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Authors:  Eric Wenzler; Dustin R Fraidenburg; Tonya Scardina; Larry H Danziger
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

8.  Characterization of Antigenic Oligosaccharides from Gram-Negative Bacteria via Activated Electron Photodetachment Mass Spectrometry.

Authors:  Christopher M Crittenden; Edwin E Escobar; Peggy E Williams; James D Sanders; Jennifer S Brodbelt
Journal:  Anal Chem       Date:  2019-03-15       Impact factor: 6.986

9.  Characterization of Lipid A Variants by Energy-Resolved Mass Spectrometry: Impact of Acyl Chains.

Authors:  Christopher M Crittenden; Lucas D Akin; Lindsay J Morrison; M Stephen Trent; Jennifer S Brodbelt
Journal:  J Am Soc Mass Spectrom       Date:  2016-12-13       Impact factor: 3.109

10.  Clinical Impact of Laboratory Implementation of Verigene BC-GN Microarray-Based Assay for Detection of Gram-Negative Bacteria in Positive Blood Cultures.

Authors:  Tamar Walker; Sandrea Dumadag; Christine Jiyoun Lee; Seung Heon Lee; Jeffrey M Bender; Jennifer Cupo Abbott; Rosemary C She
Journal:  J Clin Microbiol       Date:  2016-04-20       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.